Indivior consensus stays clear, analysts back the shares
27.06.2026 - 12:53:17 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 12:52.
Indivior (GB00BYZ0C031) sits on a consistent analyst consensus, with most houses rating the shares Buy according to recent data from MarketBeat and other aggregators. The stock trades in the U.S. via an INDV listing, offering international investors access to the specialty addiction-treatment group.
What analysts currently signal
The latest MarketBeat consensus shows Indivior with a Buy rating based on eight analyst opinions collected over the past 12 months, with seven Buys and one Hold supporting a constructive stance on the equity. MarketBeat analyst consensus for Indivior The corresponding average 12-month price target sits at around 41.83 dollars per share as of the most recent update, implying upside from the latest closing levels reported in New York trade. Detailed analyst target distribution on MarketBeat
These figures reflect the views of several Wall Street firms that follow the sector, although individual reports often adjust their targets following quarterly results or regulatory developments. The mix of Buy and Hold ratings underscores a broadly positive, but not euphoric, stance on the company’s earnings power and pipeline.
How the consensus breaks down
In the MarketBeat data, the consensus rating for Indivior is explicitly tagged as Buy, a signal that more than 60 percent of covered analysts recommend accumulating rather than merely holding the shares at current levels. MarketBeat summary of Indivior recommendations The single Hold rating in the breakdown points to at least one house that sees the valuation closer to fair value based on its own cash flow and risk assumptions.
For retail investors, the presence of multiple named research houses in the coverage universe offers a structured way to compare views on regulatory risk, litigation exposure and the durability of the addiction treatment franchise. The consensus target near 41.83 dollars incorporates those contrasting opinions into one consolidated number that can be tracked over time.
More news and analysis on the Indivior shares
Further company releases and market commentary on Indivior give additional context on how analysts update their views after earnings and regulatory decisions.
The business behind Indivior
Indivior generates its revenues primarily from prescription medicines that target opioid use disorder and other addiction-related conditions, with its long-acting formulations of buprenorphine among the better-known products in the portfolio. The group’s business model focuses on specialty pharmaceuticals, with R&D aimed at improving treatment adherence and outcomes in chronic addiction care.
Where the stock trades today
Indivior shares (GB00BYZ0C031) last closed on the U.S. market at 41.83 dollars per INDV listing on 2026-06-26, according to the latest available analyst and quote data from MarketBeat. Latest closing price and target data for Indivior
Key data on the Indivior shares
- Company: Indivior PLC
- ISIN: GB00BYZ0C031
- Ticker: INDV
- Trading venue: U.S. listing (INDV)
- Price (as of 2026-06-26, 16:00): 41.83 USD
- Sector / industry: Pharmaceuticals
- Index membership: not in a major headline equity index
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any offer. All data are based on sources believed to be reliable but cannot be guaranteed.
